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Introduction
Breast cancer is the most common form of cancer in
women from developed countries. Axillary lymph node
status is widely accepted as an important parameter for
assessing prognosis in breast cancer patients. However,
recurrence and death also occur in patients with node-
negative breast cancer (NNBC). A recurrence rate of 30%
may be expected during the first 5 years after diagnosis.
Prognostic factors such as tumour size, tumour grading,
hormone receptor status, age, histology, ploidy and prolif-
eration index are used to define subgroups of high-risk
NNBC patients [1–8]. Despite the availability of these
prognostic markers, high-risk NNBC patients cannot be
identified with sufficient accuracy. This has led to a search
for new and possibly stronger prognostic markers in order
to define new subgroups and to facilitate decision-making
with respect to appropriate therapy [2,3,9].
AGCN = average gene copy number; CART = Classification and Regression Trees; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; DFS =
disease-free survival; NNBC = node-negative breast cancer; FEC = fluorouracil, epirubicin, cyclophosphamide; OS = overall survival; PCR = poly-
merase chain reaction.
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Abstract
Background: At present, node-negative, high-risk breast
cancer patients cannot be identified with sufficient accuracy.
Consequently, further strong prognostic factors are needed.
Methods: Among 181 node-negative breast cancer (NNBC)
patients, c-myc and  HER-2/neu oncogenes were identified
prospectively using double differential PCR. The possible
impact of amplification of those oncogenes on disease-free
survival (DFS) and overall survival was examined. Furthermore,
the possible effects of adjuvant therapies on rate of recurrence
and mortality in oncogene-amplified NNBC patients were
investigated.
Results: The prevalence rates for amplification of c-myc and
HER-2/neu were 21.5% and 30.4%, respectively. On
univariate analysis, c-myc-amplified NNBCs were associated
with significantly shorter DFS at 36 months after the initial
diagnosis (85.3% versus 97.3%). As compared with
nonamplified cancers, HER-2/neu-amplified NNBCs did not
exhibit any significant differences after 36 months and
95 months. Multivariate analysis indicated that c-myc
amplification and tumour size, in contrast to HER-2/neu
amplification, oestrogen receptor status, grading and age, were
the only independent parameters for DFS. During the period of
observation, we found no evidence for an impact of
amplification of the oncogenes on overall survival in all cases.
With respect to various adjuvant systemic therapies such as
chemotherapy (cyclophosphamide, methotrexate, 5-
fluorouracil; fluorouracil, epirubicin, cyclophosphamide) and
endocrine therapy (tamoxifen), no significant differences were
identified in oncogene-amplified NNBC patients in terms of
DFS and overall survival. However, those c-myc-amplified
NNBC patients who did not receive adjuvant systemic therapy
exhibited significantly shorter DFS and overall survival as
compared with c-myc-nonamplified patients.
Conclusion: C-myc amplification appears to be a strong
prognostic marker with which to predict early recurrence in
NNBC patients. C-myc-amplified NNBC patients without adjuvant
systemic therapy experienced shorter DFS and overall survival.
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Numerous reports have described the correlation between
amplification of oncogenes and its impact on the course of
breast cancer disease [4–7,10–32]. In a meta-analysis in
which 29 studies were evaluated [33], c-myc amplification
exhibited significant but weak associations with tumour
grade, lymph node metastasis, negative progesterone
receptor status and postmenopausal status. Furthermore
c-myc amplification was significantly associated with risk
for recurrence and death. However, studies in recent
years have further shown that the c-myc gene participates
in most aspects of cellular function, including replication,
growth, metabolism, differentiation and apoptosis [34].
Amplification of the oncogene HER-2/neu has also been
shown to be indicative of poor prognosis in breast cancer.
Studies revealed that the prognostic effect of HER-2/neu
is stronger for survival than for recurrence [16,19,20,22,
27,29]. Furthermore, increased HER-2/neu levels in
primary tumours were associated with a poor response to
endocrine therapy [5,12,15,32].
A drawback of many studies of oncogenes in human
breast cancer is that usually only one oncogene was eval-
uated. Based on a series of unselected cases, in the
present study we examined the possible influence of the
amplification of the oncogenes c-myc and HER-2/neu on
disease-free survival (DFS) and overall survival (OS).
Furthermore we studied whether adjuvant therapies such
as chemotherapy and endocrine treatment or no treatment
at all had any impact on DFS and OS among oncogene-
amplified NNBC patients [1–3,8,9,32,35–38].
Patients and methods
Among 181 NNBC patients who had undergone breast-
conserving therapy or modified mastectomy combined
with axillary lymphadenectomy of level 1 and 2 (at least 10
lymph nodes per patient had been removed), c-myc and
HER-2/neu oncogenes were assessed prospectively
using double differential PCR.
Table 1 shows some clinical, histological and molecular
parameters. The median follow-up period was 42 months.
Postoperatively, the following therapies were administered
in addition to radiotherapy: tamoxifen 20 mg/day for
5 years in 54.7% of patients; and chemotherapy (six cycles
of cyclophosphamide, methotrexate, 5-fluorouracil [CMF]
or four cycles of fluorouracil, epirubicin, cyclophosphamide
[FEC]) in 33.7% of patients. Of the NNBC patients, 11.6%
did not receive any further systemic therapy.
After tissue preparation, malignant and normal tissues
were kept fresh and transported to the pathologist (U.B.).
The pathologist dissected samples for assessment of
oncogenes and hormone receptors. A positive receptor
status was defined as the presence of more than 10
fmol/mg cytosol protein. The histopathological grading
was performed according to the method of Bloom and
Richardson [39]. Lymph node sections were stained with
haemotoxylin and eosin; immunohistochemical investiga-
tions were not performed. The tumour tissues were stored
at –70°C and the DNA was isolated using the Fast Prep
System (Bio 101 Savant, Savant Instruments, Inc., Hol-
brook, NY, USA). Less than 200 mg (10–200 mg) tissue
was homogenized using FastDNA Kit in the Fast Prep
Machine. After preparing the DNA, the content was mea-
sured and the isolated DNA was stored at –20°C. General
details for the double differential PCR technique, repro-
ducibility and clinical significance were described previ-
ously [17,18,28,40]. A cutoff point of more than
2.0 average gene copy number (AGCN) was considered
to be positive for HER-2/neu amplification [40]. To calcu-
Table 1
Clinical, histological and molecular parameters of 181 node-
negative breast cancer patients














ER negative 64 (35.4)
ER positive 115 (63.5)
Unknown 2 (1.1)
PR status
PR negative 66 (36.5)
PR positive 112 (61.9)
Unknown 3 (1.7)
Oncogenes
C-myc nonamplified 142 (78.5)
C-myc amplified 39 (21.5)
HER-2/neu nonamplified 126 (69.6)
HER-2/neu amplified 55 (30.4)
C-myc and HER-2/neu coamplified 22 (12.2)
ER, oestrogen receptor; PR, progesterone receptor.Breast Cancer Research    Vol 5 No 2 Schlotter et al.
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late the cutoff point for c-myc amplification, all NNBC
patients were subjected to Classification and Regression
Trees (CART) analysis. A cutoff value of 2.1 AGCN for c-
myc oncogene led to the best distinction between
patients. Fig. 1 shows the CART analysis for all c-myc
values [41].
Results were evaluated using the SPSS system (SPSS
GmbH Software, Munich, Germany). The monoparametric
survival curves were determined using the Kaplan–Meier
method in order to estimate the impacts of intratumoural
c-myc and  HER-2/neu oncogene amplification on DFS
and OS. Statistical deviations were defined using the log-
rank test. Recurrence of disease was found at the follow-
ing locations: local (n = 2), contralateral (n = 1), axilla
(n = 2), lung (n = 1), brain (n = 1), liver (n = 1) and skin
(n = 1). During the period of observation, 14 patients died.
In order to derive relevant information regarding the
effects of oncogene amplification on the course of breast
cancer disease, the accumulated values were determined
after postoperative periods of 36 and 95 months. We
applied the multivariate Cox model to enable us to identify
independently predictive parameters [42]. Parameters
considered included the oncogenes c-myc and  HER-
2/neu, tumour size, histopathological grading, oestrogen
receptor status and age (<40 or ≥40 years).  P < 0.05
was considered statistically significant.
Results
The prevalence rates for amplification of c-myc and HER-
2/neu were 21.5% and 30.4%, respectively. Coamplifica-
tion was found in 22 patients (12.2%; Table 1). Among
those patients with c-myc amplification five recurrences
were identified (5/39 [12.8%]), and among those with
HER-2/neu amplification two recurrences (2/55 [3.6%])
were identified. Among those patients in whom neither c-
myc nor HER-2/neu were amplified four recurrences were
found (4/109 [3.6%]), and among those with coamplifica-
tion of both oncogenes two recurrences (2/22 [9.1%])
were observed. Four patients with c-myc amplification
(4/39 [10.3%]) and three patients with HER-2/neu ampli-
fication (3/55 [5.5%]) died. Nine patients who lacked
amplification of either oncogene (9/109 [8.3%]) and two
patients with coamplification (2/22 [9.1%]) died.
Using univariate analysis, c-myc-amplified cancers were
associated with a significantly lower DFS of 85.3%, as
compared with 97.3% (P = 0.0290) among c-myc-non-
amplified breast cancers. Ninety-five months after diagno-
sis (operation), the estimated DFS of c-myc-amplified
cancer patients was only 85.3%, as compared with
95.6% among c-myc-nonamplified patients (P = 0.0079).
Comparison of nonamplified cancers with HER-2/neu-
amplified cancers did not reveal any significant differences
with regard to DFS (Fig. 2).
Multivariate analysis revealed that c-myc amplification and
tumour size, in contrast to oestrogen receptor status,
grading and age, were the only independent parameters
impacting on DFS (Table 2). With regard to OS, no inde-
pendent parameters were identified among the prognostic
markers referred to above.
Figure 1
Classification and Regression Trees (CART) analysis of c-myc among
181 node-negative breast cancer patients. dd, double differential.

















































Kaplan–Meier estimation of disease-free survival (DFS) among 181
node-negative breast cancer patients.

































































0.5Regarding various adjuvant systemic therapies, such as
chemotherapy (CMF, FEC) and endocrine therapy (tamox-
ifen), no significant differences were observed with
respect to DFS and OS in c-myc-amplified and HER-2/
neu-amplified NNBC patients in comparison with non-
amplified patients. However, significantly shorter DFS and
OS were observed among c-myc-amplified patients who
did not receive systemic adjuvant therapy. No correspond-
ing associations were found among HER-2/neu-amplified
NNBC patients as compared with nonamplified patients
(Tables 3 and 4).
Discussion
Numerous clinical studies have proved axillary lymph node
status to be the dominant factor for prognosis and predic-
tion of DFS and OS in breast cancer patients. The fact of
the matter is that even among NNBC patients 25–30%




Tumour parameters and disease-free survival in 181 node-negative breast cancer patients in univariate and multivariate analyses
DFS after 36 months DFS after 95 months
Parameter Univariate P value Multivariate P value Univariate P value Multivariate P value
Tumour size 0.0223* 0.024* 0.0047* 0.002*
c-myc 0.0290* 0.013* 0.0079* 0.004*
HER-2/neu 0.2943 0.252 0.5868 0.166
Oestrogen receptor 0.6797 0.192 0.5363 0.622
Tumour grade 0.0998 0.128 0.0255* 0.663
Age < 40, ≥40 0.2330 0.965 0.0920 0.717
*P < 0.05.
Table 3
Recurrences and disease-free survival in 181 node-negative
breast cancer patients after different adjuvant systemic
therapies or no therapy
Recurrence 
Subgroup n (n [%]) DFS (P)
Chemotherapy (n = 61)
c-myc Amplified 19 3 (15.8) 0.1748
Nonamplified 42 2 (4.8)
HER-2/neu Amplified 26 1 (3.8) 0.2552
Nonamplified 35 4 (11.4)
Endocrine therapy (n = 99)
c-myc Amplified 15 1 (6.7) 0.3325
Nonamplified 84 2 (2.4)
HER-2/neu Amplified 22 1 (4.5) 0.6641
Nonamplified 77 2 (2.6)
No therapy (n = 21)
c-myc Amplified 5 1 (20.0) 0.0209*
Nonamplified 16 0 (0)
HER-2/neu Amplified 7 0 (0) 0.4969
Nonamplified 14 1 (7.1)
*P < 0.05 (log-rank test). DFS, disease-free survival.
Table 4
Mortality and overall survival in 181 node-negative breast
cancer patients after different adjuvant systemic therapies or
no therapy
Mortality 
Subgroup n (n [%]) OS (P)
Chemotherapy (n = 61)
c-myc Amplified 19 1 (5.3) 0.7442
Nonamplified 42 3 (7.1)
HER-2/neu Amplified 26 0 (0.0) 0.1042
Nonamplified 35 4 (11.4)
Endocrine therapy (n = 99)
c-myc Amplified 15 1 (6.7) 0.9846
Nonamplified 84 6 (7.1)
HER-2/neu Amplified 22 2 (9.1) 0.8307
Nonamplified 77 5 (6.5)
No therapy (n = 21)
c-myc Amplified 5 2 (40.0) 0.0098*
Nonamplified 16 1 (6.3)
HER-2/neu Amplified 7 1 (14.3) 0.5649
Nonamplified 14 2 (14.3)
*P < 0.05 (log-rank test). OS, overall survival.conferred by adjuvant chemotherapy or endocrine therapy
was examined in randomized studies [2,3,8,9,35–38].
Because adjuvant therapies may positively impact on
outcome in only around 15%, the costs of these therapies
make their routine application in all NNBC patients inap-
propriate [1]. For this reason, predictive factors that accu-
rately define subgroups of NNBC patients who may
benefit from adjuvant systemic therapy would be a great
advantage.
In the present study the oncogenes c-myc and HER-2/
neu were examined with regard to their ability to predict
DFS, OS and rate of recurrence, as well as mortality. All
patients were randomly selected from one department
(Frauenklinik Klinikum Ibbenbueren, Ibbenbueren,
Germany). C-myc amplification was identified in 21.5%
and  HER-2/neu amplification in 30.4%. Berns and
coworkers [12–14] reported amplification of c-myc in
20% and of HER-2/neu in 24% using a standard southern
blot technique. In a selected high-risk cohort of NNBC
patients, Roux-Dosseto et al. [26] applied the same
method and found prevalence rates for c-myc and HER-2/
neu amplification of 25% and 31%, respectively. Those
oncogenes were assessed in the present study using a
double differential PCR technique [17,18,40,43]. Using
this method, Brandt et al. [17] found c-myc to be amplified
in 19.7% and HER-2/neu in 16.7% of breast cancers,
without consideration of nodal status; coamplification of
those oncogenes was present in 7%. In the present study,
simultaneous amplification of both oncogenes was
observed in 12.2%. As in the present investigation, Roux-
Dosseto et al. [26] found that c-myc amplification among
NNBC patients was significantly associated with earlier
recurrence in univariate and multivariate analyses.
However,  HER-2/neu-amplified NNBC patients did not
have the same outcome. Accordingly, c-myc amplification
appears to be an independent prognostic marker, which
has greater predictive power than does oestrogen recep-
tor status and tumour grade. As early as 1992, Berns and
coworkers [11,12,14] reported that patients with c-myc-
amplified breast cancers had an unfavourable prognosis.
The first study to mention possible prognostic importance
of HER-2/neu gene amplification was reported in 1987 by
Slamon et al. [27]. That study included 187 patients with
NNBC and node-positive breast cancer; by univariate and
multivariate analyses, it revealed that HER-2/neu amplifi-
cation correlated very closely with shorter DFS and OS in
a subgroup of 87 node-positive patients. In 1993, in an
analysis of 210 patients, Press et al. [7] found that amplifi-
cation of HER-2/neu correlated with unfavourable progno-
sis with respect to DFS.
Attempts by other investigators to confirm these findings
were met with various degrees of success. Some studies
claimed that HER-2/neu status was an independent pre-
dictive factor in the case of breast cancer, whereas other
studies could not confirm this [6,14,16,19,29,30]. It is
certainly of great interest to the clinician that only two out
of five studies including more than 100 patients and with a
follow-up period of at least 3 years attributed some prog-
nostic value to HER-2/neu amplification among patients
with NNBC [6,7,16,19,28]. Almost all of the studies that
dealt with HER-2/neu status and DFS, as well as OS,
showed no benefit of this oncogene in the prognosis of
NNBC patients. In a survey conducted by Ravdin and
Chamness [24], only one [22] of 11 studies concerning
immunohistochemical overexpression of HER-2/neu indi-
cated a significant result with respect to OS in multivariate
analysis.
In the present study, 19 out of 39 c-myc-amplified patients
received chemotherapy, 15 patients received endocrine
therapy and five patients received no further therapy. The
greatest recurrence rates were noted in the group of
patients who received no therapy (20%) and in those who
received chemotherapy (16%). The lowest recurrence rate
of 7% was seen in patients treated with tamoxifen. All
patients who received endocrine therapy (n = 99) were
characterized by positive oestrogen and/or progesterone
receptor status. The proto-oncogene c-myc can be upreg-
ulated by oestrogen stimulation of hormone-dependent
breast cancer cells. Endocrine therapy with the antioestro-
gen tamoxifen can mediate the downregulation of c-myc,
culminating in cell cycle arrest [44]. Berns et al. [12]
reported that 38% of patients with amplification of c-myc
or with coamplification of c-myc and HER-2/neu profited
from endocrine therapy. C-myc-amplified patients affected
by metastatic disease showed a tendency toward longer
DFS with endocrine therapy, as compared with shorter
DFS following second-line chemotherapy. However, the
minor rate of response after chemotherapy did not corre-
late with OS. The poorer responses to chemotherapy
among patients with c-myc-amplified tumours in the
present study (recurrence rate 16%) may be in agreement
with experimental findings in erythroleukaemia cells that
the degree of cis-platinum resistance correlated directly
with the level of c-myc expression [45].
In the present study, 26 out of 55 HER-2/neu-amplified
patients received chemotherapy, 22 patients received
endocrine therapy and seven patients received no further
therapy. In total, low recurrence rates of 3.8%, 4.5% and
0% were found in the above-mentioned therapy groups,
respectively (Table 3). Compared with nonamplified
patients administered the same therapies, no significant
differences with regard to DFS and OS were observed. In
contrast to that finding, c-myc-amplified patients not
administered adjuvant systemic therapy exhibited a signifi-
cantly shorter DFS and OS than did nonamplified patients
who also received no adjuvant systemic therapy. However,
the therapy groups analyzed in the present study are
Breast Cancer Research    Vol 5 No 2 Schlotter et al.
R34small, and therefore we recommend careful interpretation
of the findings.
Higher recurrence rates or poor response to endocrine
treatment with tamoxifen in patients with HER-2/neu-
amplified hormone receptor positive tumours, as reported
in studies in node-positive or metastatic breast cancer
[12,15,32], were not observed in the present study.
Although deregulated HER-2/neu activity can strongly
stimulate cytoplasmic signalling pathways, which in turn
impinge on c-myc at multiple levels causing its deregu-
lated expression [46], this scenario does not appear to be
active in NNBC because the recurrence rate of 22 c-myc
and  HER-2/neu coamplified patients was only 9%.
However, among those patients in whom coamplification
of c-myc and HER-2/neu was absent the recurrence rate
was lower (4/109 [3.6%]). Differences in the numbers of
recurrences and deaths can be accounted for by the fact
that some deaths were not related to tumours.
Conclusion
C-myc amplification appears to represent a prognostic
marker with which early recurrence may be predicted in
NNBC patients. C-myc-amplified NNBC patients who
were not administered adjuvant systemic therapy suffer
shorter DFS and OS. C-myc could be used together with
the tumour-associated protease urokinase-plasminogen
activator and its inhibitor (i.e. plasminogen activator
inhibitor-1), after further randomized studies have been
conducted, to confirm whether NNBC patients should
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